BlackRock Discloses Passive Stake in Harvard Bioscience
Ticker: HBIO · Form: SC 13G · Filed: Jan 26, 2024 · CIK: 1123494
| Field | Detail |
|---|---|
| Company | Harvard Bioscience Inc (HBIO) |
| Form Type | SC 13G |
| Filed Date | Jan 26, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, passive-investment, SC-13G
TL;DR
**BlackRock just revealed a big, passive stake in Harvard Bioscience, signaling institutional confidence.**
AI Summary
BlackRock Inc., a massive investment firm, reported on January 26, 2024, that it holds a significant stake in Harvard Bioscience Inc. as of December 31, 2023. This filing, an SC 13G, indicates BlackRock's position as a passive investor, meaning they don't intend to influence company management. For investors, this signals that a major institutional player sees value in Harvard Bioscience, potentially lending credibility to the stock, but also means a large block of shares is held by an entity that could sell without warning if their investment thesis changes.
Why It Matters
When a giant like BlackRock holds a stock, it often signals institutional confidence, which can attract other investors and potentially stabilize the share price.
Risk Assessment
Risk Level: low — This filing indicates a passive investment by a large institution, which generally reduces volatility rather than increasing risk.
Analyst Insight
An investor might view this as a positive signal, suggesting Harvard Bioscience has met BlackRock's investment criteria. However, given BlackRock's passive role, it doesn't imply any active management changes or immediate catalysts. It's a data point for fundamental analysis, not a call to action.
Key Players & Entities
- BlackRock Inc. (company) — reporting person, investment firm
- HARVARD BIOSCIENCE INC (company) — issuer of the securities
- December 31, 2023 (date) — date of event requiring filing
- January 26, 2024 (date) — filing date
Forward-Looking Statements
- BlackRock will maintain its passive stake in Harvard Bioscience for the foreseeable future. (BlackRock Inc.) — medium confidence, target: Q4 2024
FAQ
What type of filing is this document?
This document is an SC 13G filing, specifically filed under Rule 13d-1(b) of the Securities Exchange Act of 1934.
Who is the 'reporting person' in this filing?
The reporting person, or the entity disclosing its ownership, is BlackRock Inc., with a Central Index Key (CIK) of 0001364742.
Which company's stock is the subject of this filing?
The subject company, or the issuer of the securities, is HARVARD BIOSCIENCE INC, with a CIK of 0001123494.
What is the CUSIP number for the securities mentioned in this filing?
The CUSIP number for the Common Stock of Harvard Bioscience Inc. is 416906105.
What was the 'Date of Event Which Requires Filing of this Statement'?
The date of the event which required this filing was December 31, 2023.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on January 26, 2024 regarding HARVARD BIOSCIENCE INC (HBIO).